CLEVELAND, Sept. 18, 2015 /PRNewswire/ -- GenomOncology and Thomas Jefferson University Hospital announced today that they are co-developing an interpretation and reporting system for multi-assay cancer profiling. Jefferson expects to launch the system for testing acute myeloid leukemia (AML) in their molecular pathology laboratory this fall.
AML is recognized as a highly heterogeneous disease, and as such, its molecular footprint varies. Combining karyotype analysis, fluorescence in situ hybridization (FISH) and the evaluation of mutational status of molecular markers by next generation sequencing (NGS) can lead to improved strategies for risk stratification and targeted therapy. Traditionally, the results of these disparate tests have been reported separately. To improve this situation, GenomOncology is expanding its GO Clinical Workbench™ platform to allow both independent and cumulative analysis and reporting of these assays. Jefferson's molecular pathology team, led by Stephen C. Peiper, M.D., the Peter A. Herbut Professor and Chair of the department of Pathology, Anatomy and Cell Biology, is testing this new system and guiding its development from the clinical perspective.
"For many diseases we deal with at Jefferson, the best results are obtained by applying multiple analytical techniques," said Dr. Peiper. "This is especially true for AML, for which karyotype analysis, fluorescence in situ hybridization, and next generation DNA sequencing provide complementary information. Bringing the results of each of those together in a single interpretation and reporting system simplifies our efforts and provides greater clarity to the oncologists our laboratory serves."
The two groups will be presenting initial results of the collaboration at two upcoming scientific meetings. Manuel J. Glynias, President and CEO of GenomOncology, will speak at the Individualizing Medicine Conference hosted by the Mayo Clinic, September 20-23, 2015. Members of the two teams will display further results jointly at the annual meeting of the Association for Molecular Pathology, November 5-7, 2015.
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology's technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at www.genomoncology.com.
For more information regarding this announcement, please contact: